Navigation Links
Mount Sinai researchers find new Alzheimer's disease treatment promising
Date:7/12/2009

(New York, NY July 12, 2009) Researchers at Mount Sinai School of Medicine have found that a compound called NIC5-15, might be a safe and effective treatment to stabilize cognitive performance in patients with mild to moderate Alzheimer's disease. The two investigators, Giulio Maria Pasinetti, M.D., Ph.D. , and Hillel Grossman, M.D., presented Phase IIA preliminary clinical findings at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD) in Vienna on Sunday, July 12.

NIC5-15's potential to preserve cognitive performance will be further evaluated in a Phase IIB clinical trial. Early evidence suggests that NIC5-15 is a safe and tolerable natural compound that may reduce the progression of Alzheimer's disease-related dementia by preventing the formation of beta-amyloid plaque, a waxy substance that accumulates between brain cells and impacts cognitive function. .

"With Alzheimer's disease affecting 5.2 million Americans, another 5 million with early-state disease, and nearly a half million new cases reported annually, treatments like NIC5-15 would make a significant difference in the lives of many Alzheimer's patients," said Dr. Pasinetti, Professor of Psychiatry, Professor of Neuroscience and Professor of Geriatrics and Adult Development, in the Department of Psychiatry at Mount Sinai School of Medicine. "We are hopeful that the follow up clinical study will support this preliminary evidence."

"There are no FDA-approved Alzheimer's disease modifying drugs available today," said Dr. Hillel Grossman, Assistant Professor of Psychiatry, Co-Director of the Clinical Research Core of the Alzheimer's Disease Research Center, and Clinical Director of the Mount Sinai Memory and Aging Center. "Current drugs approved for use help maintain cognitive function, but only for a limited time. NIC5-15 is part of a new class of natural compound we found to have the potential of precluding the generation of β-a
'/>"/>

Contact: Mount Sinai Newsroom
Newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Paramount Acquisition Corp. Announces Chem Rx Expansion into Albany, New York Market
2. Mount Sinai & ENT and Allergy Associates, LLP affiliate to fight cancer
3. Paramount Acquisition Corp. Announces Record Date of October 1, 2007 for Proposed Acquisition of Chem Rx
4. Kaiser Permanente study: Alcohol amount, not type -- wine, beer, liquor -- triggers breast cancer
5. Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx
6. Fred Hutchinson Cancer Research Center Announces the First-Ever Expedition to an Unclimbed Mountain in the Name of Cancer Research
7. Iron Mountain Acquires RMS Services - USA, Inc.
8. Surge in U.S. Cases of Rocky Mountain Spotted Fever
9. Oregon Scientific to Sponsor First-Ever Rock Concert on Mount Everest
10. Mount Sinai recognized as Center of Excellence for Research in Alzheimers disease
11. Paramount Completes Acquisition of Chem Rx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Surgeons at the Forbes Hospital ... Network, are exploring an innovative use of Google ... Zonal Reminder (VIZR), to assist in the care of ... is a wearable technology with an optical head-mounted display ... communicate with the Internet via natural language voice commands. ...
(Date:3/2/2015)... March 02, 2015 Ticket Down is ... the Hollywood Bowl . This popular site has reduced ... promo code JIMMY-BUFFETT-2015 for added savings. , Parrotheads in ... performer will be headlining at the Hollywood Bowl for ... be on Thursday, October 22nd and it will be ...
(Date:3/2/2015)... Doctors in Novara, Italy have found that ... outcomes for people with mesothelioma than other clinical factors. ... new study on the Surviving Mesothelioma website. , ... Piedmont followed the cases of 172 mesothelioma patients ... fluid. , “Persistent lung expansion after pleural talc ...
(Date:3/2/2015)... 2015 Burns Engineering's Lab-to-Lab Calibration ... Secondary Standard Platinum Resistance Thermometers (SSPRTs) and industrial ... or less . . . guaranteed. ... (Lab Code 200706-0), ISO 9001 and 17025 Certified ... is -196°C to 500°C, both ITS-90 and Callendar-van ...
(Date:3/2/2015)... The minimally invasive surgical instruments market is ... to reach $14,133.0 million by 2019 from $10,526.2 ... advantages of minimally invasive surgeries over traditional open ... surgeries and increasing number of surgical procedures among ... invasive surgical instruments market. , For More Details ...
Breaking Medicine News(10 mins):Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 2Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 3Health News:Cheap Jimmy Buffett Tickets Hollywood Bowl: Ticket Down Slashes Prices on Jimmy Buffett Tickets at the Hollywood Bowl in Los Angeles/Hollywood, CA 2Health News:New Research Links Talc Treatment Response with Mesothelioma Prognosis, According to Surviving Mesothelioma 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2
... In a decision of broad impact to medical malpractice ... refused to apply the state,s "cap" on non-economic damages ... when the Maryland General Assembly revised the damage cap ... could recover from negligent doctors and hospitals, the legislature ...
... April 21 Hudson Institute is pleased to welcome ... of Health and Human Services (HHS) under George W. ... Troy will write on health care, medical innovation, and ... around the corner, we are very fortunate to have ...
... Cancer Research,s 100th Annual Meeting 2009 -SOUTH SAN FRANCISCO, ... (Nasdaq: PARD ), a biopharmaceutical company focused ... from a Phase 1 clinical study of an oral ... showed that the bioavailability of oral picoplatin is nearly ...
... device for the treatment of depression named one ... 21 - NeuroStar(R) TMS (Transcranial Magnetic Stimulation) Therapy ... treatment cleared by the FDA for Major Depressive ... Design Excellence Award (MDEA). The award will be ...
... 21 Frost & Sullivan presented ... Pacific,s Healthcare sector at the 2009 Frost ... Awards held today at the InterContinental hotel in ... consecutive year, the awards banquet recognised companies across ...
... HRC ) fiscal 2009 second quarter earnings release will ... participate in a webcast the following morning on May 5, 2009 ... Holdings, Inc.,s Fiscal 2009 Second Quarter Release for the quarter ended ... NYSE close on Monday, May 4, 2009. The release will ...
Cached Medicine News:Health News:Judge Holds Maryland Damages Cap Not Applicable to Malpractice Cases 2Health News:Judge Holds Maryland Damages Cap Not Applicable to Malpractice Cases 3Health News:Former HHS Deputy Secretary Tevi Troy Joins Hudson Institute 2Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 2Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 3Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 4Health News:Photos: NeuroStar TMS Therapy(R) Recipient of Medical Design Excellence Award 2Health News:Photos: NeuroStar TMS Therapy(R) Recipient of Medical Design Excellence Award 3Health News:Outstanding Healthcare Companies in Asia Pacific Honored 2Health News:Outstanding Healthcare Companies in Asia Pacific Honored 3Health News:Outstanding Healthcare Companies in Asia Pacific Honored 4Health News:Outstanding Healthcare Companies in Asia Pacific Honored 5Health News:Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Second Quarter Earnings Webcast 2
(Date:3/2/2015)... 2015  DURECT Corporation (Nasdaq: DRRX ... the successful completion of a Phase 1 clinical ... DUR-928 is an endogenous, small-molecule, new chemical entity ... diseases such as nonalcoholic fatty liver disease (NAFLD) ... injuries such as acute kidney injury (AKI).        ...
(Date:3/2/2015)... 2, 2015  Intrexon Corporation (NYSE: ... announced its fourth quarter and full year results ... Recent Developments: , Acquired ActoGeniX, a European ... in cellular therapeutics and other innovative products.  Its ... food-grade microbes ( Lactococcus lactis ) to generate ...
(Date:3/2/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial ... 31, 2014. Financial highlights for the fourth quarter include revenues ... or $0.04 per share. This compares to revenues of $12.5 ... per share, for the fourth quarter of 2013. Financial highlights ... and a net loss of $68.4 million, or $0.56 per ...
Breaking Medicine Technology:DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9
... Optimal for Subcellular Fractionation, ... x g (30,000 rpm) with ... from 0.25 up to 85 ... 2° C to 40° C ...
... Centra-GP6R general purpose centrifuges offer high-volume versatility ... rotor options, making them ideal for a ... Versatility , Four- or six-place sealed ... oil tube rotors offered , Lare capacity ...
... Centrifuges feature powerful, maintenance-free motors, ... of rotors for unparalleled application ... in one: a high capacity ... harvesting; a high-speed centrifuge for ...
... MicroCentrifuge Two Strip Rotor hold 16 0.2ml ... with). Simply close the polycarbonate lid to ... open. Starts and stops in seconds. Maximum ... g. Only five inches in diameter. Also ...
Medicine Products: